A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06687759
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to learn what happens to calderasib in a healthy person's body over time and how it is cleared from the body.

Key Dates

Start date
Jun 26, 2024
Status verified
Apr 2026
Primary completion
Aug 7, 2024
Completion
Aug 7, 2024

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Carbon-14 radiolabeled [14C] MK-1084
    Participants receive single oral dose of calderasib on Day 1.

Primary Outcome Measure

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of plasma Calderasib [ Time Frame: Predose and at designated timepoints up to Day 15 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortea CRU Madison (Site 0001)MadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortea CRU Madison· Madison, WI

Related Studies